Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

le Coutre, Philipp; G. Ottmann, Oliver; J. Giles, Francis; Kim, Dong‐Wook; E. Cortes, Jörge; Gattermann, Norbert; F. Apperley, Jane; A. Larson, Richard; Abruzzese, Elisabetta; G. O’Brien, Stephen; Kuliczkowski, Kazimierz; Hochhaus, Andreas; Mahon, François-Xavier; Saglio, Giuseppe; Gobbi, Marco; Kwong, Yok‐Lam; Baccarani, Michele; P. Hughes, Timothy; Martinelli, Giovanni; P. Radich, Jerald; Zheng, Ming; Shou, Yaping; M. Kantarjian, Hagop

doi:10.1182/blood-2007-04-083196

Public

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Published in Blood • Nov 30, 2007

Authors:

Philipp le Coutre

Oliver G. Ottmann

Francis J. Giles

Abstract

Patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia (CML-AP) have very limited therapeutic options. Nilotinib is a highly selective BCR-ABL tyrosine kinase inhibitor. This phase 2 trial was designed to characterize the efficacy and safety of nilotinib (400 ...

Subject

Nilotinib

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!